Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody

Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location

(2017) Masahide Matsuda et al.   JOURNAL OF CLINICAL NEUROSCIENCE

First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake

(2016) N. Pandit-Taskar et al.   JOURNAL OF NUCLEAR MEDICINE

Performance of SPECT in the differential diagnosis of glioma recurrence from radiation necrosis

(2015) Hui Zhang et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis: a characteristic of malignant lymphoma

(2015) Fumiyuki Yamasaki et al.   JOURNAL OF NEUROSURGERY

Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases

(2014) Natsuko Nomura et al.   Cancer Cell International

Correlation between 18F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas

(2014) Nobuyuki Kawai et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Comparison of 11C-Methionine, 11C-Choline, and 18F-Fluorodeoxyglucose-PET for Distinguishing Glioma Recurrence from Radiation Necrosis

(2013) Shunsuke TAKENAKA et al.   NEUROLOGIA MEDICO-CHIRURGICA

PET imaging with 89Zr: From radiochemistry to the clinic

(2012) Melissa A. Deri et al.   NUCLEAR MEDICINE AND BIOLOGY

Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study

(2011) Keishi Makino et al.   ANNALS OF NUCLEAR MEDICINE

Prostate-Specific Membrane Antigen as a Potential Novel Vascular Target for Treatment of Glioblastoma Multiforme

(2011) A Gabriella Wernicke et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma

(2011) M. Hutterer et al.   JOURNAL OF NUCLEAR MEDICINE

3'-Deoxy-3'-18F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab

(2011) J. Schwarzenberg et al.   JOURNAL OF NUCLEAR MEDICINE

Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI

(2010) Yong Hwy Kim et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Standardized methods for the production of high specific-activity zirconium-89

(2009) Jason P. Holland et al.   NUCLEAR MEDICINE AND BIOLOGY

Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

(2008) Sith Sathornsumetee et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibodies and Antimatter: The Resurgence of Immuno-PET

(2008) A. M. Wu   JOURNAL OF NUCLEAR MEDICINE